Compounds targeting alpha4-beta7 integrin

Patent metadata

Field	Value
Publication number	US-2023295235-A1
Application number	US-202118011997-A
Country	US
Kind code	A1
Filing date	Jun 25, 2021
Priority date	Jun 29, 2020
Publication date	Sep 21, 2023
Grant date	—

Abstract

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.

First claim

1 . A compound of formula (I):
or a pharmaceutically acceptable salt or solvate thereof, wherein the stereochemistry of the carbon atom at each of positions 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a and 7b may each be independently (R) or (S).

2 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 1a and 1b is (S).

3 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 2a and 2b is (S).

4 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 3a and 3b is (S).

5 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 4a and 4b is (S).

6 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 5a and 5b is (S).

7 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 6a and 6b is (S).

8 . The compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein the stereochemistry of the carbon atom at each of positions 7a and 7b is (R).

9 . The compound of claim 1 having formula (Ia):

or pharmaceutically acceptable salt or solvate thereof.

10 . A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt or solvate thereof of claim 1 , and a pharmaceutically acceptable carrier.

11 . (canceled)

12 . A method of treating inflammation or an autoimmune disease in a patient in need of said treatment, the method comprising administering to the patient a therapeutically effective amount of the compound or pharmaceutically acceptable salt or solvate thereof of claim 1 .

13 . The method of claim 12 , wherein the inflammation or autoimmune disease is gastrointestinal.

14 . A method of treating a condition in a patient, the condition selected from the group consisting of Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn’s disease, celiac disease, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, cholangitis, pericholangitis, primary sclerosing cholangitis, human immunodeficiency virus (HIV) infection in the GI tract, graft versus host disease, and primary biliary sclerosis, the method comprising administering to the patient a therapeutically effective amount of the compound or pharmaceutically acceptable salt or solvate thereof of claim 1 .

15 . The method of claim 14 , wherein the condition is Inflammatory Bowel Disease (IBD).

16 . The method of claim 14 , wherein the condition is ulcerative colitis.

17 . The method of claim 14 , wherein the condition is Crohn’s disease.

18 . A method of treating a local or systemic infection of a virus or retrovirus in a patient, the method comprising administering to the patient a therapeutically effective amount of the compound or pharmaceutically acceptable salt or solvate thereof of claim 1 .

19 . The method of claim 18 , wherein the virus is HIV.

Assignees

• Zealand Pharma As

Inventors

• Roughton Andrew
• Patel Narendrakumar
• Kafal Adam Paul
• Vazquez Manuel Perez
• Hickey Jennifer
• Chakka Sai Kumar
• Morshed Monzur

Classifications

• C07K7/56 Primary

  the cyclisation not occurring through 2,4-diamino-butanoic acid · CPC title

• A61P31/18

  for HIV · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title